On August 18, Anlan Dejian announced the completion of Series A financing of nearly 100 million yuan, exclusively invested by Qiming Venture Capital. The funds raised in this round will mainly be used to accelerate the domestic registration clinical trial process for the core product OpusOne™, and fully support the application and development of early clinical trials overseas.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.